Molecular profiling for precision medicine in cervical cancer

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K16425
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Tokai University
• Principal Investigator: Machida Hiroko 東海大学, 医学部, 助教 (40803507)
• Project Period (FY): 2020-04-01 – 2022-03-31
• Keywords: 子宮頸癌 / 分子標的薬 / ゲノム解析 / 腺癌 / ROS1 / 次世代シーケンス / EGFR / ALK

Outline of Final Research Achievements

This NGS-based molecular profiling (a single center, observation study in Japan) investigated the frequency of alterations in cancer-related genes in a Japanese cohort of cervical cancer. Our data suggests the frequent alterations in ROS1, EGFR, and ALK genes in cervical adenocarcinoma, may provided epigenetic therapeutic strategies for the treatment in certain cervical cancer patients.

Free Research Field

外科系臨床医学・産婦人科

Academic Significance and Societal Importance of the Research Achievements

現在、ROS1阻害薬であるクリゾチニブ、エヌトレクチニブなどの分子標的薬が、ROS1融合遺伝子陽性の非小細胞肺癌には保険適用となっている。これらの薬剤はROS1融合遺伝子陽性の腫瘍に効果を示す可能性があると期待されており、予後不良な子宮頸部腺癌とくにType2の頸部腺癌で有効となる可能性がある。